Anti-angiogenic therapies for metastatic colorectal cancer

Anna Dorothea A D W Wagner, Dirk Arnold, Axel F Grothey, Johannes Haerting, Susanne Unverzagt

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Background: Angiogenesis inhibitors have been developed to block tumour angiogenesis and target vascular endothelial cells. While some of them have already been approved by the health authorities and are successfully integrated into patient care, many others are still under development, and the clinical value of this approach has to be established. Objectives: To assess the efficacy and toxicity of targeted anti-angiogenic therapies, in addition to chemotherapy, in patients with metastatic colorectal cancer. Primary endpoints are both progression-free and overall survival. Response rates, toxicity and secondary resectability were secondary endpoints. Comparisons were first-line chemotherapy in combination with angiogenesis inhibitor, to the same chemotherapy without angiogenesis inhibitor; and second-line chemotherapy, to the same chemotherapy without angiogenesis inhibitor. Search strategy: We searched the Cochrane Central Register of Controlled Trials, MEDLINE, as well as proceedings from ECCO, ESMO and ASCO until November 2008. In addition, reference lists from trials were scanned, experts in the field and drug manufacturers were contacted to obtain further information. Selection criteria: Randomized controlled trials on targeted anti-angiogenic drugs in metastatic colorectal cancer (MCRC). Data collection and analysis: Data collection and analysis was performed, according to a previously published protocol. Because individual patient data was not provided, aggregate data had to be used for the analysis. Summary statistics for the primary endpoints were hazard ratios (HR's) and their 95% confidence intervals. Main results: At present, eligible first line trials for this meta-analysis were available for bevacizumab (5 trials including 3101 patients) and vatalanib (1 trial which included 1168 patients). The overall HR's for PFS (0.61, 95% CI 0.45 - 0.83) and OS (0.81, 95% 0.73 - 0.90) for the comparison of first-line chemotherapy, with or without bevacizumab, confirms significant benefits in favour of the patients treated with bevacizumab. However, the effect on PFS shows significant heterogeneity. For second-line chemotherapy, with or without bevacizumab, a benefit in both PFS (HR 0.61, 95% CI 0.51 - 0.73) and OS (HR 0.75, 95% CI 0.63-0.89) was demonstrated in a single, randomized trial. While differences in treatment-related deaths and 60-day mortality were not significant, higher incidences in grade III/IV hypertension, arterial thrombembolic events and gastrointestinal perforations were observed in the patients treated with bevacizumab. For valatanib, currently available data showed a non-significant benefit in PFS and OS. Authors' conclusions: The addition of bevacizumab to chemotherapy of metastatic colorectal cancer prolongs both PFS and OS in first-and second-line therapy

Original languageEnglish (US)
Article numberCD005392
JournalCochrane Database of Systematic Reviews
Issue number3
DOIs
StatePublished - 2009

Fingerprint

Angiogenesis Inhibitors
Colorectal Neoplasms
Drug Therapy
Therapeutics
Combination Drug Therapy
MEDLINE
Patient Selection
Disease-Free Survival
Meta-Analysis
Bevacizumab
Patient Care
Randomized Controlled Trials
Endothelial Cells
Confidence Intervals
Hypertension
Mortality
Incidence
Health
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology (medical)

Cite this

Wagner, A. D. A. D. W., Arnold, D., Grothey, A. F., Haerting, J., & Unverzagt, S. (2009). Anti-angiogenic therapies for metastatic colorectal cancer. Cochrane Database of Systematic Reviews, (3), [CD005392]. https://doi.org/10.1002/14651858.CD005392.pub3

Anti-angiogenic therapies for metastatic colorectal cancer. / Wagner, Anna Dorothea A D W; Arnold, Dirk; Grothey, Axel F; Haerting, Johannes; Unverzagt, Susanne.

In: Cochrane Database of Systematic Reviews, No. 3, CD005392, 2009.

Research output: Contribution to journalArticle

Wagner, Anna Dorothea A D W ; Arnold, Dirk ; Grothey, Axel F ; Haerting, Johannes ; Unverzagt, Susanne. / Anti-angiogenic therapies for metastatic colorectal cancer. In: Cochrane Database of Systematic Reviews. 2009 ; No. 3.
@article{82814752a6014c02a8732f388f2ad21b,
title = "Anti-angiogenic therapies for metastatic colorectal cancer",
abstract = "Background: Angiogenesis inhibitors have been developed to block tumour angiogenesis and target vascular endothelial cells. While some of them have already been approved by the health authorities and are successfully integrated into patient care, many others are still under development, and the clinical value of this approach has to be established. Objectives: To assess the efficacy and toxicity of targeted anti-angiogenic therapies, in addition to chemotherapy, in patients with metastatic colorectal cancer. Primary endpoints are both progression-free and overall survival. Response rates, toxicity and secondary resectability were secondary endpoints. Comparisons were first-line chemotherapy in combination with angiogenesis inhibitor, to the same chemotherapy without angiogenesis inhibitor; and second-line chemotherapy, to the same chemotherapy without angiogenesis inhibitor. Search strategy: We searched the Cochrane Central Register of Controlled Trials, MEDLINE, as well as proceedings from ECCO, ESMO and ASCO until November 2008. In addition, reference lists from trials were scanned, experts in the field and drug manufacturers were contacted to obtain further information. Selection criteria: Randomized controlled trials on targeted anti-angiogenic drugs in metastatic colorectal cancer (MCRC). Data collection and analysis: Data collection and analysis was performed, according to a previously published protocol. Because individual patient data was not provided, aggregate data had to be used for the analysis. Summary statistics for the primary endpoints were hazard ratios (HR's) and their 95{\%} confidence intervals. Main results: At present, eligible first line trials for this meta-analysis were available for bevacizumab (5 trials including 3101 patients) and vatalanib (1 trial which included 1168 patients). The overall HR's for PFS (0.61, 95{\%} CI 0.45 - 0.83) and OS (0.81, 95{\%} 0.73 - 0.90) for the comparison of first-line chemotherapy, with or without bevacizumab, confirms significant benefits in favour of the patients treated with bevacizumab. However, the effect on PFS shows significant heterogeneity. For second-line chemotherapy, with or without bevacizumab, a benefit in both PFS (HR 0.61, 95{\%} CI 0.51 - 0.73) and OS (HR 0.75, 95{\%} CI 0.63-0.89) was demonstrated in a single, randomized trial. While differences in treatment-related deaths and 60-day mortality were not significant, higher incidences in grade III/IV hypertension, arterial thrombembolic events and gastrointestinal perforations were observed in the patients treated with bevacizumab. For valatanib, currently available data showed a non-significant benefit in PFS and OS. Authors' conclusions: The addition of bevacizumab to chemotherapy of metastatic colorectal cancer prolongs both PFS and OS in first-and second-line therapy",
author = "Wagner, {Anna Dorothea A D W} and Dirk Arnold and Grothey, {Axel F} and Johannes Haerting and Susanne Unverzagt",
year = "2009",
doi = "10.1002/14651858.CD005392.pub3",
language = "English (US)",
journal = "Cochrane Database of Systematic Reviews",
issn = "1361-6137",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Anti-angiogenic therapies for metastatic colorectal cancer

AU - Wagner, Anna Dorothea A D W

AU - Arnold, Dirk

AU - Grothey, Axel F

AU - Haerting, Johannes

AU - Unverzagt, Susanne

PY - 2009

Y1 - 2009

N2 - Background: Angiogenesis inhibitors have been developed to block tumour angiogenesis and target vascular endothelial cells. While some of them have already been approved by the health authorities and are successfully integrated into patient care, many others are still under development, and the clinical value of this approach has to be established. Objectives: To assess the efficacy and toxicity of targeted anti-angiogenic therapies, in addition to chemotherapy, in patients with metastatic colorectal cancer. Primary endpoints are both progression-free and overall survival. Response rates, toxicity and secondary resectability were secondary endpoints. Comparisons were first-line chemotherapy in combination with angiogenesis inhibitor, to the same chemotherapy without angiogenesis inhibitor; and second-line chemotherapy, to the same chemotherapy without angiogenesis inhibitor. Search strategy: We searched the Cochrane Central Register of Controlled Trials, MEDLINE, as well as proceedings from ECCO, ESMO and ASCO until November 2008. In addition, reference lists from trials were scanned, experts in the field and drug manufacturers were contacted to obtain further information. Selection criteria: Randomized controlled trials on targeted anti-angiogenic drugs in metastatic colorectal cancer (MCRC). Data collection and analysis: Data collection and analysis was performed, according to a previously published protocol. Because individual patient data was not provided, aggregate data had to be used for the analysis. Summary statistics for the primary endpoints were hazard ratios (HR's) and their 95% confidence intervals. Main results: At present, eligible first line trials for this meta-analysis were available for bevacizumab (5 trials including 3101 patients) and vatalanib (1 trial which included 1168 patients). The overall HR's for PFS (0.61, 95% CI 0.45 - 0.83) and OS (0.81, 95% 0.73 - 0.90) for the comparison of first-line chemotherapy, with or without bevacizumab, confirms significant benefits in favour of the patients treated with bevacizumab. However, the effect on PFS shows significant heterogeneity. For second-line chemotherapy, with or without bevacizumab, a benefit in both PFS (HR 0.61, 95% CI 0.51 - 0.73) and OS (HR 0.75, 95% CI 0.63-0.89) was demonstrated in a single, randomized trial. While differences in treatment-related deaths and 60-day mortality were not significant, higher incidences in grade III/IV hypertension, arterial thrombembolic events and gastrointestinal perforations were observed in the patients treated with bevacizumab. For valatanib, currently available data showed a non-significant benefit in PFS and OS. Authors' conclusions: The addition of bevacizumab to chemotherapy of metastatic colorectal cancer prolongs both PFS and OS in first-and second-line therapy

AB - Background: Angiogenesis inhibitors have been developed to block tumour angiogenesis and target vascular endothelial cells. While some of them have already been approved by the health authorities and are successfully integrated into patient care, many others are still under development, and the clinical value of this approach has to be established. Objectives: To assess the efficacy and toxicity of targeted anti-angiogenic therapies, in addition to chemotherapy, in patients with metastatic colorectal cancer. Primary endpoints are both progression-free and overall survival. Response rates, toxicity and secondary resectability were secondary endpoints. Comparisons were first-line chemotherapy in combination with angiogenesis inhibitor, to the same chemotherapy without angiogenesis inhibitor; and second-line chemotherapy, to the same chemotherapy without angiogenesis inhibitor. Search strategy: We searched the Cochrane Central Register of Controlled Trials, MEDLINE, as well as proceedings from ECCO, ESMO and ASCO until November 2008. In addition, reference lists from trials were scanned, experts in the field and drug manufacturers were contacted to obtain further information. Selection criteria: Randomized controlled trials on targeted anti-angiogenic drugs in metastatic colorectal cancer (MCRC). Data collection and analysis: Data collection and analysis was performed, according to a previously published protocol. Because individual patient data was not provided, aggregate data had to be used for the analysis. Summary statistics for the primary endpoints were hazard ratios (HR's) and their 95% confidence intervals. Main results: At present, eligible first line trials for this meta-analysis were available for bevacizumab (5 trials including 3101 patients) and vatalanib (1 trial which included 1168 patients). The overall HR's for PFS (0.61, 95% CI 0.45 - 0.83) and OS (0.81, 95% 0.73 - 0.90) for the comparison of first-line chemotherapy, with or without bevacizumab, confirms significant benefits in favour of the patients treated with bevacizumab. However, the effect on PFS shows significant heterogeneity. For second-line chemotherapy, with or without bevacizumab, a benefit in both PFS (HR 0.61, 95% CI 0.51 - 0.73) and OS (HR 0.75, 95% CI 0.63-0.89) was demonstrated in a single, randomized trial. While differences in treatment-related deaths and 60-day mortality were not significant, higher incidences in grade III/IV hypertension, arterial thrombembolic events and gastrointestinal perforations were observed in the patients treated with bevacizumab. For valatanib, currently available data showed a non-significant benefit in PFS and OS. Authors' conclusions: The addition of bevacizumab to chemotherapy of metastatic colorectal cancer prolongs both PFS and OS in first-and second-line therapy

UR - http://www.scopus.com/inward/record.url?scp=70049102736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70049102736&partnerID=8YFLogxK

U2 - 10.1002/14651858.CD005392.pub3

DO - 10.1002/14651858.CD005392.pub3

M3 - Article

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

SN - 1361-6137

IS - 3

M1 - CD005392

ER -